1Y Close · As of Aug 26, 2026
PharmGen Science operates in the Pharmaceuticals sector.
Legal name: PharmGen Science, Inc.
In fiscal year 2024, PharmGen Science (004720) reported revenue of 171.3 billion KRW, up 2.7% from 166.8 billion KRW a year earlier.
Operating profit was 10.6 billion KRW and net income was 2.8 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 73.2 billion KRW, with a P/B of 0.50.
These figures can be verified in the DART filing (receipt no. 20260515001314).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2024 | 171.3B | 10.6B | 2.8B |
| 2023 | 166.8B | 9.1B | 5.7B |
| 2022 | 150.9B | 7.5B | 70.1B |
Checks
No items require attention at this time.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-14 | Semi-Annual Report (2026.06) |